Develop and commercialize pharmaceutical products. Focus on oncology and anti-infectives therapeutic areas. Now — the numbers.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
We do not hold enough financial data on this company to point to a strength.
The price action doesn’t yet back an upward turn.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.